These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 11449771)

  • 1. [Anagrelide in primary thrombocythemia].
    Knutsen H; Hysing J
    Tidsskr Nor Laegeforen; 2001 May; 121(12):1478-82. PubMed ID: 11449771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anagrelide in the treatment of thrombocythemia essential (ET)].
    Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
    Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
    Prescrire Int; 2006 Jun; 15(83):83-6. PubMed ID: 16764090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
    Iványi JL; Marton É; Plander M; Szendrei T
    Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany.
    Petrides PE; Beykirch MK; Trapp OM
    Eur J Haematol; 1998 Aug; 61(2):71-6. PubMed ID: 9714517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
    Birgegård G; Björkholm M; Kutti J; Lärfars G; Löfvenberg E; Markevärn B; Merup M; Palmblad J; Mauritzson N; Westin J; Samuelsson J
    Haematologica; 2004 May; 89(5):520-7. PubMed ID: 15136214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial.
    Gisslinger H; Buxhofer-Ausch V; Hodisch J; Radinoff A; Karyagina E; Kyrcz-Krzemień S; Abdulkadyrov K; Gerbutavicius R; Melikyan A; Burgstaller S; Hus M; Kłoczko J; Yablokova V; Tzvetkov N; Całbecka M; Shneyder T; Warzocha K; Jurgutis M; Kaplanov K; Jilma B; Schoergenhofer C; Klade C
    Br J Haematol; 2019 May; 185(4):691-700. PubMed ID: 30919941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of essential thrombocythemia in childhood.
    Scherer S; Ferrari R; Rister M
    Pediatr Hematol Oncol; 2003; 20(5):361-5. PubMed ID: 12775533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
    Balduini CL; Bertolino G; Noris P; Ascari E
    Haematologica; 1992; 77(1):40-3. PubMed ID: 1398280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia.
    Mills AK; Taylor KM; Wright SJ; Bunce I; Eliadis P; Brigden MC; Seeley G; Bashford J; Olsen T; Rentoul A; Kelly C
    Aust N Z J Med; 1999 Feb; 29(1):29-35. PubMed ID: 10200810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anagrelide: a review of its use in the management of essential thrombocythaemia.
    Wagstaff AJ; Keating GM
    Drugs; 2006; 66(1):111-31. PubMed ID: 16398570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
    N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial].
    Ge X; Yang L; Jin J; Qian W; Li J; Yang R; Cao X; Jiang B; Wang Z; Hou M; Zhang W; Xiao Z; Zhao Y; Gao D; Zhang X; Wang S; Sun A; Fu J; Su L; Li K
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):547-52. PubMed ID: 26304075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
    Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ;
    Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
    Burkhard R; Adam H; Widmer L; Honegger HP
    Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anagrelide, a selective thrombocytopenic agent.
    Oertel MD
    Am J Health Syst Pharm; 1998 Oct; 55(19):1979-86. PubMed ID: 9784784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia.
    Gugliotta L; Tieghi A; Tortorella G; Scalzulli PR; Ciancia R; Lunghi M; Cacciola E; Cacciola R; Candoni A; Crugnola M; Codeluppi K; Usala E; Specchia G; Martinelli V; Palmieri F; Pierri I; Liberati AM; Iurlo A; Grossi A; Vannucchi AM; Vianelli N; Mazzucconi MG
    Leuk Res; 2011 Dec; 35(12):1557-63. PubMed ID: 21764130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A long-term study of young patients with essential thrombocythemia treated with anagrelide.
    Mazzucconi MG; Redi R; Bernasconi S; Bizzoni L; Dragoni F; Latagliata R; Santoro C; Mandelli F
    Haematologica; 2004 Nov; 89(11):1306-13. PubMed ID: 15531452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.
    Petrides PE
    Expert Opin Pharmacother; 2004 Aug; 5(8):1781-98. PubMed ID: 15264993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of essential thrombocythemia with anagrelide: a ten-year experience].
    Kornblihtt LI; Vassallu PS; Heller P; Molinas FC
    Medicina (B Aires); 2002; 62(3):231-6. PubMed ID: 12150005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.